-
A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR) — a measure of suicidality — in patients with stimulant use disorder.
Sanchez K, Killian MO, Mayes TL, Greer TL, Trombello JM, Lindblad R, Grannemann BD, Carmody TJ, Rush AJ, Walker NR. A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR) -- a measure of suicidality -- in patients with stimulant use disorder. Journal of Psychiatric Research 2018;102:65-71.
-
Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients.
John WS, Zhu H, Mannelli P, Schwartz RP, Subramaniam GA, Wu L. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. Drug and Alcohol Dependence 2018;187:79-87.
-
Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: A qualitative study of patients, providers, and staff.
McNeely J, Kumar PC, Rieckmann TR, Sedlander E, Farkas S, Chollak C, Kannry JL, Vega A, Waite EA, Peccoralo LA, Rosenthal RN, McCarty D, Rotrosen J. Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: A qualitative study of patients, providers, and staff. Addiction Science & Clinical Practice 2018;13:8.
-
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial.
Squeglia LM, Tomko RL, Baker NL, McClure EA, Book GA, Gray KM. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug and Alcohol Dependence 2018;185:17-22.
-
Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
Barbosa-Leiker C, McPherson S, Layton ME, Burduli E, Roll JM, Ling W. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. American Journal of Drug and Alcohol Abuse 2018;44(4):488-496.
-
Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.
Crist RC, Li J, Doyle GA, Gilbert A, Dechairo BM, Berrettini WH. Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. American Journal of Drug and Alcohol Abuse 2018;44(4):431-440. doi: 10.1080/00952990.2017.1420795.
-
Impact of behavioral drug abuse treatment on sexual risk behaviors: An integrative data analysis of eight trials conducted within the National Drug Abuse Treatment Clinical Trials Network.
Brown JL, Eriksen MD, Gause NK, Brody GH, Sales JM. Impact of behavioral drug abuse treatment on sexual risk behaviors: An integrative data analysis of eight trials conducted within the National Drug Abuse Treatment Clinical Trials Network. Prevention Science 2018;19(6):761-771.
-
Enhancing patient navigation with contingent incentives to improve healthcare behaviors and viral load suppression of persons with HIV and substance use.
Stitzer ML, Hammond AS, Matheson T, Sorensen JL, Feaster DJ, Duan R, Gooden LK, del Rio C, Metsch LR. Enhancing patient navigation with contingent incentives to improve healthcare behaviors and viral load suppression of persons with HIV and substance use. AIDS Patient Care and STDS 2018;32(7):288-296.
-
Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.
Baker NL, Gray KM, Sherman BJ, Morella K, Sahlem GL, Wagner AM, McRae-Clark AL. Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug and Alcohol Dependence 2018;178:270-277.
-
Prevalence of behavioral health conditions across frequency of cannabis use among adult primary care patients in Washington State.
Lapham GT, Lee AK, Caldeiro RM, Glass JE, Carrell DS, Richards JE, Bradley KA. Prevalence of behavioral health conditions across frequency of cannabis use among adult primary care patients in Washington State. Journal of General Internal Medicine 2018;33(11):1833-1835.